The Effect of Examined Lymph Nodes and Lymph Node Ratio on Pathological Nodal Classification in the Lung Adenosquamous Carcinoma After Lobectomy.
adenosquamous carcinoma
lymph node
lymph node ratio
non-small cell lung cancer
survival
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
03
2022
accepted:
23
05
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
The effects of examined lymph nodes (LNs) and lymph node ratio (LNR) on pN classification and the prognosis are unclear in lung adenosquamous carcinoma (ASC) patients. Thus, this study aimed to investigate the significance of LNs and LNR in the prognosis of ASC and the impact of the abovementioned factors on the pN classification. Patients diagnosed with pathological stage T1-4N0-2M0 ASC from the Surveillance Epidemiology and End Results database were included in the study. The primary clinical endpoint was cancer-specific survival (CSS). The optimal cutoff values of the LNs and LNR were determined. An LN indicator, including pN0 #LNs ≤9, pN0 #LNs >9, pN The cohort of 1,416 patients were included in the study. The level of LNs stratified the patients without metastasis of lymph nodes (pN0 #LNs ≤9 vs. pN0 #LNs >9, unadjusted hazard ratio [HR] = 1.255, We explored clinicopathological factors affecting prognosis in resected lung ASC patients. Besides, the LN indicator was confirmed to be played an essential role in affecting the survival rate in ASC patients. The high-level LNs or low-level LNR might be corelated to improved survival outcomes.
Identifiants
pubmed: 35756483
doi: 10.3389/fsurg.2022.909810
pmc: PMC9218197
doi:
Types de publication
Journal Article
Langues
eng
Pagination
909810Informations de copyright
Copyright © 2022 Feng, Liu, Huang, Shi and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Surg Oncol. 2020 May;121(6):1027-1035
pubmed: 32026478
BMC Pulm Med. 2020 Sep 11;20(1):242
pubmed: 32917179
World J Surg Oncol. 2020 Dec 7;18(1):322
pubmed: 33287841
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
BMC Cancer. 2022 Mar 2;22(1):225
pubmed: 35236309
Ann Thorac Surg. 2013 Oct;96(4):1163-1170
pubmed: 23998409
Lung Cancer. 2021 May;155:183-190
pubmed: 33558063
Lung Cancer. 2019 Jul;133:136-143
pubmed: 31200820
Eur J Cardiothorac Surg. 2021 Apr 13;59(3):617-623
pubmed: 33200178
J Thorac Dis. 2013 Oct;5(5):585-92
pubmed: 24255770
Ann Thorac Surg. 2019 Jun;107(6):1647-1655
pubmed: 30682353
J Thorac Dis. 2018 Jun;10(6):3225-3231
pubmed: 30069318
BMC Cancer. 2021 Sep 9;21(1):1009
pubmed: 34496775
J Thorac Oncol. 2011 Nov;6(11):1865-71
pubmed: 21964529
Front Genet. 2022 Jan 05;12:798131
pubmed: 35069695
World J Surg Oncol. 2016 Nov 25;14(1):295
pubmed: 27884195
Front Surg. 2022 Feb 11;9:735102
pubmed: 35223973
J Thorac Dis. 2020 Oct;12(10):5552-5560
pubmed: 33209388
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Front Surg. 2021 Apr 29;8:604880
pubmed: 33996882
Clin Lung Cancer. 2018 Jul;19(4):e421-e430
pubmed: 29609906
Eur Radiol. 2022 Feb;32(2):1065-1077
pubmed: 34453574
Lung Cancer. 2011 Oct;74(1):25-9
pubmed: 21371773
Mol Cancer. 2022 Jan 3;21(1):4
pubmed: 34980131